Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients

Pilot Study Examining the Effects of Combined Pharmacotherapy (Zyban/NRT)/Behavioral Treatment on Smoking Cessation Among MMT Patients.

The purpose of this pilot study is to examine the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among methadone maintenance therapy patients.

This is a one-arm, open label pilot study of MMT patients to determine whether bupropion, nicotine replacement therapy, and behavioral counseling is a feasible and potentially effective intervention for smoking cessation. The smoking behaviors of participants will be be followed for 6 months post quit-date to determine effect-size estimates for a future, large scale trial.

Inclusion Criteria:

• Patients in long-term methadone maintenance treatment
• Patient smokes at least 10 cigarettes per day, are stable on their use of methadone (phase 2 or higher treatment), smoked for at least 1 year, be willing to participate for 6 months, and not have used bupropion or nicotine replacement therapy for 6 months

Exclusion Criteria:

• Patients who use prescription drug regimens that might affect methadone or bupropion metabolism
• Patients with cardiovascular disease, asthma, COPD
• Patients who are pregnant or breastfeeding
• Patients with regular use of alcohol, other illicit drugs, or other types of tobacco (chewing or pipe for example)